Human fibrinogen concentrate - CSL Behring

Drug Profile

Human fibrinogen concentrate - CSL Behring

Alternative Names: Fibrinogen Concentrate (Human); Haemocomplettan P; RiaSTAP

Latest Information Update: 17 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CSL Behring
  • Developer CSL Behring; Rigshospitalet
  • Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Afibrinogenaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Afibrinogenaemia
  • Phase III Surgical blood loss
  • Phase II Haemorrhage

Most Recent Events

  • 15 Jan 2018 Yale University and CSL Behring withdraws the PERFECT PPH phase I/II trial prior to enrolment, before January 2018 (NCT02528708)
  • 20 Apr 2017 CSL Behring completes a clinical trial in Haemorrhage (Adjunctive treatment) in United Kingdom (IV) (UKCRN19181)
  • 02 Mar 2016 CSL Behring completes the FIBCON trial in Surgical blood loss (In infants, In neonates) in United Kingdom (EudraCT2013-003532-68)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top